Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Myocardial Infarct Clinical Trial

Official title:
Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects

Status Completed

Clinical Trial Summary

The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01264783
Study type	Interventional
Source	Revalesio Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	July 2011
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01179776` - Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)	Phase 1/Phase 2
Terminated	`NCT00237471` - Impact of Tight Glycaemic Control in Acute Myocardial Infarction	Phase 4
Active, not recruiting	`NCT02967965` - CARdioprotection in Myocardial Infarction
Completed	`NCT00560742` - Efficacy Study of Intramuscular or Intracoronary Injection of Autologous Bone Marrow Cells to Treat Scarred Myocardium	Phase 2
Completed	`NCT01033617` - IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG	N/A
Completed	`NCT00338156` - Observational Study of the Remodelling Process Following Myocardial Infarct	N/A